Skip to main content

Table 5 Duration of hospitalization and estimated associated costs in participating countries

From: Resource use by patients hospitalized with community-acquired pneumonia in Europe: analysis of the REACH study

Country

Total duration of hospitalization in REACH study, days, median

Secondary-level hospital*

Estimated cost of median length of stay in REACH study, US$ (based on secondary-level hospital costs)

Tertiary-level/teaching hospital

Estimated cost of median length of stay in REACH study, US$ (based on tertiary-level hospital costs)

Cost per bed/day, local currency

Cost per bed/day, US$

Cost per bed/day, local currency

Cost per bed/day, US$

Belgium

10.0

424.70

624.60

6246.00

549.20

807.64

8076.40

France

11.0

396.00

582.40

6406.40

512.10

753.06

8283.66

Germany

9.0

401.10

589.84

5308.56

518.60

762.69

6864.21

Greece

7.0

266.20

391.42

2739.94

344.20

506.13

3542.91

Italy

11.0

337.80

496.80

5464.80

436.80

642.38

7066.18

The Netherlands

9.0

493.40

725.58

6530.22

638.00

938.21

8443.89

Portugal

10.0

199.50

293.35

2933.50

257.90

379.31

3793.10

Spain

9.5

307.60

452.30

4296.85

397.70

584.85

5556.08

Turkey

10.0

147.00

112.88

1128.80

190.00

145.96

1459.60

United Kingdom

7.0

311.40

576.60

4036.20

402.60

745.56

5218.92

  1. *Secondary-level hospitals = hospitals intended primarily for treating referral cases, with bed size ranging from 200 to 800 beds.
  2. Tertiary-level/teaching hospitals = hospitals intended for referral cases, with a teaching component and highly specialised staff and technical equipment, including ICU and bed size ranging from 300 to 1,500 beds.
  3. Local currency is Euro for all countries except Turkey (Turkish Lira) and United Kingdom (GBP).
  4. Costs are estimates of unit costs for 2007 and 2008 base-year values. They represent costs for public facilities in urban areas that are operating at 80% capacity.
  5. Cost estimates represent only the ‘hotel’ component of hospital costs, excluding the costs of drugs and diagnostic tests but including costs such as personnel, capital and food costs.